NCT07089992

A Study of Pembrolizumab in People With Ultra-Rare Sarcomas

URSa-1: A Minibasket Study of Pembrolizumab in Ultra-Rare Sarcomas

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to find out if pembrolizumab is a useful treatment that causes few or mild side effects in people with ultra-rare sarcoma. The researchers will also study how the immune system responds to the study treatment. Pembrolizumab is a type of drug called a PD-1 inhibitor. It is designed to block a protein called programmed cell death protein 1 (PD-1) that usually acts as a "brake" on the immune system. Blocking this protein is like releasing the brakes, so that the immune system can target cancer cells and destroy them.

Conditions

• Sarcoma

Interventions

Type	Name	Description
DRUG	Pembrolizumab	Q 6 weeks IV infusion Day 1 of each 6-week cycle, up to 8 doses

Timeline

• Start date: 2025-12-04
• Primary completion: 2028-12-01
• Completion: 2028-12-01
• First posted: 2025-07-29
• Last updated: 2025-12-16

Locations

6 sites across 1 country: United States

Regulatory

• FDA-regulated drug study